NASDAQ: NRSNNeurosense Therapeutics Ltd Stock
$0.99-0.02 (-1.98%)
Updated Apr 23, 2025
NRSN Price
$0.99
Fair Value Price
N/A
Market Cap
$22.93M
52 Week Low
$0.51
52 Week High
$1.50
P/E
-1.83x
P/B
8.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.77
Operating Cash Flow
-$10M
Beta
0.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NRSN Overview
NeuroSense Therapeutics Ltd. is developing treatment for patients with debilitating neurodegenerative diseases.The company's lead product, PrimeC, is a novel oral formulation in clinical trials to treat amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease, and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics was incorporated in 2017 and is headquartered in Herzliya, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NRSN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NRSN
Ranked#145 of 461
Ranked#145 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.09 | A | |
| $23.12 | A |
Be the first to know about important NRSN news, forecast changes, insider trades & much more!
NRSN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NRSN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRSN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NRSN is poor value based on its book value relative to its share price (8.88x), compared to the US Biotechnology industry average (4.25x)
P/B vs Industry Valuation
NRSN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NRSN due diligence checks available for Premium users.
Valuation
NRSN fair value
Fair Value of NRSN stock based on Discounted Cash Flow (DCF)
Price
$0.99
Fair Value
$0.18
Overvalued by
440.58%
NRSN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NRSN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.83x
Industry
-284.95x
Market
26.95x
NRSN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.88x
Industry
4.25x
NRSN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NRSN's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.8M
Profit Margin
0%
NRSN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.6M
Liabilities
$2.0M
Debt to equity
0.77
NRSN's short-term assets ($4.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRSN's short-term assets ($4.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRSN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NRSN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NRSN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NRSN vs Biotech Stocks
Neurosense Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.